Essais liés9clinical trials
VillePeorialocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT03984448

Ouvrir le site du centre

Essais cliniques associés

9
MoléculeIndication / populationPhaseNCTTitreStatut
Biospecimen Collection Cancer Phase 3 NCT07097142 Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study RECRUITING
Bevacizumab Cancer Phase 3 NCT07198074 Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer RECRUITING
Investigational PFO Closure Device Accident vasculaire cérébral Non applicable NCT05069558 OCCLUFLEX — Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion ACTIVE_NOT_RECRUITING
Biospecimen Collection SEP Phase 2/3 NCT03984448 Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas ACTIVE_NOT_RECRUITING
Biopsy Procedure SEP Phase 2 NCT02143414 Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING
Azacitidine Cancer Phase 2 NCT05554406 Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) RECRUITING
Acalabrutinib Cancer Phase 2 NCT04115631 A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma ACTIVE_NOT_RECRUITING
Biospecimen Collection Cancer Phase 3 NCT04267848 Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) RECRUITING
liposomal doxorubicin Cancer Phase 2 NCT01078441 Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant TERMINATED